How Peptide Testing Works: HPLC, LC-MS, and Why It Matters

BPC-157 is a synthetic peptide studied for its ability to accelerate repair in tendons, ligaments, muscles, and bone. What makes it different from most recovery protocols is its primary mechanism: it stimulates angiogenesis — the growth of new blood vessels — directly into damaged tissue, feeding cells the oxygen and nutrients they need to rebuild. Originally discovered in human gastric juice, this 15-amino-acid compound has been the subject of dozens of preclinical studies and case reports across orthopaedics and sports medicine. Here is what the research actually shows.

TB-500 is the synthetic 43-amino-acid analog of Thymosin Beta-4, a naturally occurring actin-sequestering protein found in virtually every mammalian tissue — platelets, white blood cells, heart, brain, skin, and muscle. Unlike site-specific repair peptides, TB-500 acts systemically: it promotes actin polymerisation, drives endothelial cell migration, stimulates angiogenesis, and reduces pro-inflammatory signalling across multiple tissue types simultaneously. It has been studied for cardiac repair post-myocardial infarction, corneal wound healing, dermal repair, neuroprotection, and musculoskeletal recovery. When stacked with BPC-157 — the combination known as the Wolverine Stack — the two peptides create a complementary repair cascade: BPC-157 concentrates angiogenesis and tenocyte recruitment at the specific injury site while TB-500 delivers systemic cellular machinery and anti-inflammatory cover to support recovery throughout the body.

GHK-Cu (glycyl-L-histidyl-L-lysine-copper(II)) is a naturally occurring copper-binding tripeptide first isolated from human plasma by Pickart in 1973. Plasma levels decline sharply with age — dropping approximately 60% between ages 20 and 60 — correlating with diminished wound healing capacity, reduced skin elasticity, and slower connective tissue repair. Unlike topical copper peptides in cosmetics (which cannot penetrate beyond the epidermis), injected GHK-Cu delivers the copper tripeptide systemically, activating collagen and glycosaminoglycan synthesis, metalloproteinase-mediated tissue remodelling, and antioxidant gene expression throughout the body. It holds a unique position in EU cosmetics regulation (INCI: Copper Tripeptide-1) — the only peptide of this class with unambiguous INCI status — reflecting decades of safety data that most research peptides lack.